[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Dips While Market Gains: Key Facts",
    "summary": "AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=0076bffb38267ce206058111271824f07aa5a0c7aae2b110b6ff6fc4017fe74b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768517104,
      "headline": "AbbVie (ABBV) Stock Dips While Market Gains: Key Facts",
      "id": 138143063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=0076bffb38267ce206058111271824f07aa5a0c7aae2b110b6ff6fc4017fe74b"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory",
    "summary": "AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.",
    "url": "https://finnhub.io/api/news?id=d32cb94e1965aa897643fbc66adedec18d5080abcb45c8c0b3f9998995c8c6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768491780,
      "headline": "The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory",
      "id": 138122677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.",
      "url": "https://finnhub.io/api/news?id=d32cb94e1965aa897643fbc66adedec18d5080abcb45c8c0b3f9998995c8c6d5"
    }
  },
  {
    "ts": null,
    "headline": "ANIP Stock Rises 7% in a Week: Here's What You Should Know",
    "summary": "ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.",
    "url": "https://finnhub.io/api/news?id=b73c960e9d2c206dc34c3f4213873ed3564b58ae817f1fc444accb36a06fdd39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768483920,
      "headline": "ANIP Stock Rises 7% in a Week: Here's What You Should Know",
      "id": 138121580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.",
      "url": "https://finnhub.io/api/news?id=b73c960e9d2c206dc34c3f4213873ed3564b58ae817f1fc444accb36a06fdd39"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
    "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
    "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768483560,
      "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
      "id": 138121561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
      "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5"
    }
  },
  {
    "ts": null,
    "headline": "IGD: Middling Performance, But Could Be A Hedge Against A Richly Valued Market",
    "summary": "The Voya Global Equity Dividend and Premium Opportunity Fund offers a 10.43% yield via an equity portfolio with a covered call strategy. See why I rate the IGD stock a Hold.",
    "url": "https://finnhub.io/api/news?id=c0ecc0cdd587cab5a4e3436abca2a919563e6a8d8d0a2ca8ece0a75d8c78eeed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768468807,
      "headline": "IGD: Middling Performance, But Could Be A Hedge Against A Richly Valued Market",
      "id": 138121056,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2216425295/image_2216425295.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Voya Global Equity Dividend and Premium Opportunity Fund offers a 10.43% yield via an equity portfolio with a covered call strategy. See why I rate the IGD stock a Hold.",
      "url": "https://finnhub.io/api/news?id=c0ecc0cdd587cab5a4e3436abca2a919563e6a8d8d0a2ca8ece0a75d8c78eeed"
    }
  }
]